Shenzhen Kangtai Biological Products Co., Ltd.
Simbolis: 300601.SZ
SHZ
22.57
CNYRinkos kaina šiandien
33.0556
P/E santykis
-0.2996
PEG koeficientas
24.02B
MRK kapitalizacija
- 0.01%
DIV pajamingumas
Shenzhen Kangtai Biological Products Co., Ltd. (300601-SZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4599.59 | 1758.9 | 1458.4 | 3549.5 | ||||||||||||
balance-sheet.row.short-term-investments | 720.3 | 563.4 | 440.8 | 725.6 | ||||||||||||
balance-sheet.row.net-receivables | 11088.33 | 2819.2 | 2414.7 | 1991.2 | ||||||||||||
balance-sheet.row.inventory | 3331.33 | 772.9 | 727.8 | 1058.2 | ||||||||||||
balance-sheet.row.other-current-assets | 2231.38 | 45 | 573.9 | 741.7 | ||||||||||||
balance-sheet.row.total-current-assets | 21250.63 | 5396 | 5174.9 | 7340.7 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 22827.08 | 5756.9 | 5176.1 | 4116.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 2009.08 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2009.08 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.long-term-investments | 3309.55 | 2696.2 | 2041.3 | 99.4 | ||||||||||||
balance-sheet.row.tax-assets | 2537.58 | 630.3 | 708.3 | 558.6 | ||||||||||||
balance-sheet.row.other-non-current-assets | 7180.63 | 101.7 | 210.6 | 1297.6 | ||||||||||||
balance-sheet.row.total-non-current-assets | 37863.92 | 9689.4 | 8611.5 | 6808.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 59114.56 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.account-payables | 2706.32 | 791.2 | 434.1 | 708.2 | ||||||||||||
balance-sheet.row.short-term-debt | 1082.42 | 174.3 | 273.7 | 800.1 | ||||||||||||
balance-sheet.row.tax-payables | 80.82 | 25.9 | 173.4 | 98.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 8995.05 | 2372.2 | 2015.7 | 1938 | ||||||||||||
Deferred Revenue Non Current | 1296.77 | 328.7 | 383.1 | 349.5 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 102.52 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 3352.38 | 1757.1 | 1600.8 | 2.8 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 10251.7 | 2463.6 | 2461.2 | 2364.1 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-liab | 20652.76 | 5215 | 4801 | 4982.2 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 4467.66 | 1116.9 | 1120.5 | 687.1 | ||||||||||||
balance-sheet.row.retained-earnings | 8977.1 | 2216.7 | 1641.1 | 2435 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 18507.33 | 3117.4 | 3036 | 2417.5 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 6181.04 | 3090.6 | 3187.7 | 3627.1 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 38133.13 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 59114.56 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.minority-interest | -0.04 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 38133.09 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 59114.56 | - | - | - | ||||||||||||
Total Investments | 3836.89 | 3259.6 | 440.8 | 99.4 | ||||||||||||
balance-sheet.row.total-debt | 10077.46 | 2546.6 | 2289.4 | 2738.1 | ||||||||||||
balance-sheet.row.net-debt | 6198.17 | 1351 | 1271.7 | -811.4 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 709.91 | -132.7 | 1263.4 | 679.2 | |||||||||||
cash-flows.row.depreciation-and-amortization | 35.58 | 200.9 | 404.7 | 92.9 | |||||||||||
cash-flows.row.deferred-income-tax | -40.19 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.stock-based-compensation | 6.38 | 10 | 30 | 104.8 | |||||||||||
cash-flows.row.change-in-working-capital | -411.69 | -604.5 | -275.6 | -461.7 | |||||||||||
cash-flows.row.account-receivables | -417.18 | -488.8 | 273.9 | -796.5 | |||||||||||
cash-flows.row.inventory | 8.68 | 220.7 | -746.7 | -209.7 | |||||||||||
cash-flows.row.account-payables | 0 | -131 | 146.5 | 451.3 | |||||||||||
cash-flows.row.other-working-capital | -3.19 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.other-non-cash-items | 318.01 | 1277.6 | 179.2 | -68.6 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 884.06 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -700.32 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.acquisitions-net | 0.9 | 0.1 | 0.2 | 1227.7 | |||||||||||
cash-flows.row.purchases-of-investments | -1042 | -3518 | -1100 | -2625 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 831.5 | 2224.4 | 2198.2 | 13.7 | |||||||||||
cash-flows.row.other-investing-activites | -57.67 | -2.4 | 1.7 | -1226.7 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -909.91 | -2606.3 | -1440.3 | -3836.9 | |||||||||||
cash-flows.row.debt-repayment | -289.42 | -1070.4 | -26.5 | -256 | |||||||||||
cash-flows.row.common-stock-issued | -58.07 | 132.7 | -2.1 | -1 | |||||||||||
cash-flows.row.common-stock-repurchased | -201.98 | -20.6 | 2.1 | -0.2 | |||||||||||
cash-flows.row.dividends-paid | -237.32 | -622.2 | -220.4 | -207.3 | |||||||||||
cash-flows.row.other-financing-activites | 390.66 | 1115.6 | 2699 | 4243.3 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -64.64 | -464.9 | 2452.2 | 3778.7 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.04 | -1.7 | -1 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -77.03 | -2527.1 | 2663.1 | 381.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 3832.6 | 994.1 | 3521.3 | 858.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 3909.63 | 3521.3 | 858.1 | 476.5 | |||||||||||
cash-flows.row.operating-cash-flow | 884.06 | 545.7 | 1652.3 | 439.8 | |||||||||||
cash-flows.row.capital-expenditure | -700.32 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.free-cash-flow | 183.74 | -764.7 | -888.1 | -786.8 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3167.52 | 3451.8 | 3157.4 | 3652.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 531.13 | 622.8 | 499.9 | 986.4 | ||||||||||||
income-statement-row.row.gross-profit | 2636.4 | 2829.1 | 2657.5 | 2665.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 511.11 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 84.74 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1132.01 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | -76.32 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.operating-expenses | 1900.36 | 2054.2 | 2020.8 | 1071.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 2431.49 | 2677 | 2520.8 | 2058.4 | ||||||||||||
income-statement-row.row.interest-income | 117.17 | 115.6 | 132.6 | 114.9 | ||||||||||||
income-statement-row.row.interest-expense | 119.01 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 1132.01 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 88.6 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | -76.32 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.total-operating-expenses | 88.6 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.interest-expense | 119.01 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 185.67 | 240.7 | 200.9 | 676.6 | ||||||||||||
income-statement-row.row.ebitda-caps | 947.68 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 675.06 | 774.8 | 747 | 1452.2 | ||||||||||||
income-statement-row.row.income-before-tax | 763.66 | 940.3 | -338.2 | 1439.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 53.79 | 79 | -205.5 | 175.9 | ||||||||||||
income-statement-row.row.net-income | 709.91 | 861.3 | -132.7 | 1263.4 |
Dažnai užduodami klausimai
Kas yra Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) bendras turtas?
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) bendras turtas yra 15085358535.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 1451440163.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.832.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 0.165.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.224.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.213.
Kas yra Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 861303903.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 2546554090.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 2054244031.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 876163610.000.